ArticleAnnals of cardiothoracic surgery2019
Traditional and non-traditional anticoagulation management during extracorporeal membrane oxygenation.
Article in Annals of cardiothoracic surgery, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 66 citations in OpenAlex.
- Challenges and opportunities in ECMO monitoring: A mixed-methods appraisal.The journal of extra-corporeal technology · 2026Review
- Anticoagulation-free strategy within the first 24 h of extracorporeal cardiopulmonary resuscitation in refractory cardiac arrest patients: a retrospective cohort study.European journal of medical research · 2025Article
- A silicon membrane microfluidic oxygenator for use as an artificial placenta with minimal anticoagulation.Bioengineering & translational medicine · 2025Article
- Antithrombin during veno-venous extracorporeal membrane oxygenation with heparin anticoagulation: A single-center cohort study.Perfusion · 2025Article
- Decreased bleeding and thrombotic complications on extracorporeal membrane oxygenation support following an updated anticoagulation protocol.JTCVS open · 2025Article
- The relationship between different anticoagulation monitoring indicators and heparin doses in adult patients with extracorporeal cardiopulmonary resuscitation.Frontiers in cardiovascular medicine · 2025Article
- Pharmacokinetic and pharmacodynamic analyses of nafamostat in ECMO patients: comparing central vein and ECMO machine samples.Frontiers in pharmacology · 2025Article
- Anticoagulation management during veno-venous ECMO support because of ARDS: Single-center experience.Heliyon · 2024Article
- Inferior vena cava thrombosis in patients undergoing extracorporeal membrane oxygenation: a case series and literature review.BMC anesthesiology · 2024Article
- Anticoagulation during extracorporeal membrane oxygenation.The Cochrane database of systematic reviews · 2024Article
- Review
- Anticoagulation Management in V-V ECMO Patients: A Multidisciplinary Pragmatic Protocol.Journal of clinical medicine · 2024Review
- Sustaining Life versus Altering Life-Saving Drugs: Insights to Explain the Paradoxical Effect of Extracorporeal Membrane Oxygenation on Drugs.Journal of clinical medicine · 2023Review
- Artificial placenta support of extremely preterm ovine fetuses at the border of viability for up to 336 hours with maintenance of systemic circulation but reduced somatic and organ growth.Frontiers in physiology · 2023Article
- Pediatric Extracorporeal Membrane Oxygenation Anticoagulation and Monitoring: Where We Were and Where Are We Now?The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG · 2023Article
- Incidence and risk factors of deep vein thrombosis after extracorporeal life support.Artificial organs · 2022Observational
- Antioxidant System and Ions Concentrations After Femoral Neck and Resurfacing Hip Arthroplasty.Medical science monitor : international medical journal of experimental and clinical research · 2022Article
- Serum Total Bilirubin With Hospital Survival in Adults During Extracorporeal Membrane Oxygenation.Frontiers in medicine · 2022Article
- Antithrombotic and anticoagulation therapies in cardiogenic shock: a critical review of the published literature.ESC heart failure · 2021Review
- Prior Antiplatelet Therapy and Stroke Risk in Critically Ill Patients Undergoing Extracorporeal Membrane Oxygenation.International journal of environmental research and public health · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Unfractionated heparin (UFH) is the anticoagulant of choice during extracorporeal membrane oxygenation (ECMO) support. Despite its favorable pharmacologic properties, management of heparin anticoagulation during ECMO remains a major challenge. To date, little is known about the optimal monitoring strategy or the heparin dose offering the best safety/efficacy profile. Therefore, it remains unclear if the heparin dose should be adapted to target a specific "clotting time" [e.g., activated clotting time (ACT) or activated partial thromboplastin time (aPTT)] or a heparin concentration, measured by coagulation factor anti-Xa assay. In addition, no study has compared the relevance of modern viscoelastic coagulation tests over the single value of a clotting time or heparin concentration value. Although guidelines for anticoagulation during ECMO support have been published, the absence of evidence limits the quality of the recommendations provided, which explains the major intra- and inter-institutional variability observed. Large prospective multicenter trials are urgently needed to investigate the optimal anticoagulation management strategy during ECMO support.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.